title: Evaluating immune responses after sipuleucel-T therapy.
abstract: Following FDA approval of sipuleucel-T in 2010 for metastatic castration resistant prostate cancer (mCRPC), several studies have described the effect of sipuleucel-T on peripheral immune responses. Retrospective associations have also been made with immune responses and survival. A recently published study by Fong et al. was the first to characterize the immune response of sipuleucel-T in the tumor microenvironment. The findings of this study have been hypothesis generating, yet it remains unclear whether the peri-tumor immune response described is predictive of survival. Increasing evidence suggests that radiographic or PSA progression does not accurately reflect survival with sipuleucel-T and other immunotherapies. Finding an immune biomarker which can accurately reflect clinical benefit and validating it prospectively offers the potential for a predictive indicator of response in an area where none currently exists.
authors.affiliation: a Genitourinary Malignancies Branch ; Center for Cancer Research ; National Cancer Institute ; Bethesda , MD USA.
authors.forename: Julius
authors.initials: J
authors.lastname: Strauss
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality* / Q000473:pathology; D015996:Survival Rate; D014020:Tissue Extracts / Q000276:immunology* / Q000494:pharmacology; D059016:Tumor Microenvironment
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T
keywords: GU malignancies; immune response; prostate cancer; sipuleucel-T; urology